References
Andersen, G., Meiffren, G., Famulla, S., Heise, T., Ranson, A., Seroussi, C., Eloy, R., Gaudier, M., Charvet, R., & Chan, Y. P. (2021). ADO09, a co‐formulation of the amylin analogue pramlintide and the insulin analogue A21G, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism ,23 (4), 961-970.
Aroda, V. R., Henry, R. R., Han, J., Huang, W., DeYoung, M. B., Darsow, T., & Hoogwerf, B. J. (2012). Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. Clinical therapeutics , 34 (6), 1247-1258. e1222.
Association, A. D. (2010). Diagnosis and classification of diabetes mellitus. Diabetes Care , 33 (Supplement 1), S62-S69.
Bae, C. S., & Song, J. (2017). The role of glucagon-like peptide 1 (GLP1) in type 3 diabetes: GLP-1 controls insulin resistance, neuroinflammation and neurogenesis in the brain. International journal of molecular sciences , 18 (11), 2493.
Bækdal, T. A., Donsmark, M., Hartoft‐Nielsen, M. L., Søndergaard, F. L., & Connor, A. (2021). Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study.Clinical pharmacology in drug development , 10 (5), 453-462.
Balakrishnan, M., Sudarsanam, P., & Nethaji, D. (2021). Formulation and Evaluation of Controlled-release matrix Vildagliptin tablets.International Journal of Clinical Pharmacokinetics and Medical Sciences , 1 (2), 35-41.
Barnett, A. (2007). Exenatide. Expert opinion on pharmacotherapy ,8 (15), 2593-2608.
Barnett, A. H. (2011). Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes. Core evidence , 6 , 67.
[Record #118 is using a reference type undefined in this output style.]
Blech, S., Ludwig-Schwellinger, E., Gräfe-Mody, E. U., Withopf, B., & Wagner, K. (2010). The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans. Drug Metabolism and Disposition , 38 (4), 667-678.
Bode, B. (2012). An overview of the pharmacokinetics, efficacy and safety of liraglutide. Diabetes research and clinical practice ,97 (1), 27-42.
Boulton, D., Li, L., Frevert, E. U., Tang, A., Castaneda, L., Vachharajani, N. N., Kornhauser, D. M., & Patel, C. G. (2011). Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. Clinical pharmacokinetics , 50 (4), 253-265.
Boulton, D. W. (2017). Clinical pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase-4 inhibitor. Clinical pharmacokinetics , 56 (1), 11-24.
Bray, G. M. (2006). Exenatide. American journal of health-system pharmacy , 63 (5), 411-418.
Brønden, A., Naver, S. V., Knop, F. K., & Christensen, M. (2015). Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. Expert Opinion on Drug Metabolism and Toxicology , 11 (9), 1493-1503.
Bruni, G., Ghione, I., Berbenni, V., Cardini, A., Capsoni, D., Girella, A., Milanese, C., & Marini, A. (2021). The Physico-Chemical Properties of Glipizide: New Findings. Molecules , 26 (11), 3142.
Burness, C. B. (2015). Omarigliptin: first global approval.Drugs , 75 (16), 1947-1952.
Burness, C. B., & Scott, L. J. (2015). Dulaglutide: a review in type 2 diabetes. BioDrugs , 29 (6), 407-418.
Bush, M., Scott, R., Watanalumlerd, P., Zhi, H., & Lewis, E. (2012). Effects of multiple doses of albiglutide on the pharmacokinetics, pharmacodynamics, and safety of digoxin, warfarin, or a low-dose oral contraceptive. Postgraduate medicine , 124 (6), 55-72.
Ceriello, A., De Nigris, V., Iijima, H., Matsui, T., & Gouda, M. (2019). The unique pharmacological and pharmacokinetic profile of teneligliptin: implications for clinical practice. Drugs ,79 (7), 733-750.
Chavan, K. H., Kedar, N., & Jadhav, R. I. (2020). An overview of recent development towards the synthesis of Linagliptin a DPP-4 inhibitor.Chemistry & Biology Interface , 10 (5).
Chia, C. W., & Egan, J. M. (2020). Incretins in obesity and diabetes.Annals of the New York Academy of Sciences , 1461 (1), 104-126.
Cho, Y. M., Deerochanawong, C., Seekaew, S., Suraamornkul, S., Benjachareonwong, S., Sattanon, S., Chamnan, P., Sirirak, T., Kosachunhanun, N., & Pratipanawatr, T. (2020). Efficacy and safety of gemigliptin as add‐on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus (ZEUS II study). Diabetes, Obesity and Metabolism , 22 (1), 123-127.
Choi, H. Y., Kim, Y. H., Kim, M. J., Lee, S. H., Bang, K., Han, S., Lim, H.-S., & Bae, K.-S. (2014). Evaluation of pharmacokinetic drug interactions between gemigliptin (dipeptidylpeptidase-4 inhibitor) and glimepiride (sulfonylurea) in healthy volunteers. Drugs in R&D ,14 (3), 165-176.
Christensen, M., Knop, F. K., Holst, J. J., & Vilsboll, T. (2009). Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. IDrugs: the investigational drugs journal ,12 (8), 503-513.
Christou, G. A., Katsiki, N., Blundell, J., Fruhbeck, G., & Kiortsis, D. N. (2019). Semaglutide as a promising antiobesity drug. Obesity Reviews , 20 (6), 805-815.
Clements, J. N., Isaacs, D., Hartman, R. E., & Gambill, K. (2021). Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus. Clinical Pharmacokinetics , 60 (2), 153-163.
Copley, K., McCowen, K., Hiles, R., Nielsen, L. L., Young, A., & Parkes, D. G. (2006). Investigation of exenatide elimination and its in vivo and in vitro degradation. Current drug metabolism ,7 (4), 367-374.
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., & Roell, W. C. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Molecular metabolism , 18 , 3-14.
Cui, H., Zhao, C.-Y., Lv, Y., Wei, M.-J., Zhu, Y., Ma, X.-Z., Xia, Y.-H., Tian, J.-H., Ma, Y., & Liu, Y. (2021). Safety, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Doses of PEGylated Exenatide (PB-119) in Healthy Volunteers. European Journal of Drug Metabolism and Pharmacokinetics , 46 (2), 265-275.
Cvetković, R. S., & Plosker, G. L. (2007). Exenatide. Drugs ,67 (6), 935-954.
Damholt, B., Golor, G., Wierich, W., Pedersen, P., Ekblom, M., & Zdravkovic, M. (2006). An open‐label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once‐daily glucagon‐like peptide‐1 analogue liraglutide. The Journal of Clinical Pharmacology , 46 (6), 635-641.
Davis, P. N., Ndefo, U. A., Oliver, A., & Payton, E. (2015). Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus. American Journal of Health-System Pharmacy , 72 (13), 1097-1103.
de la Peña, A., Cui, X., Geiser, J., & Loghin, C. (2017). No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide.Clinical pharmacokinetics , 56 (11), 1415-1427.
Deeks, E. D. (2012). Linagliptin. Drugs , 72 (13), 1793-1824.
Dineen, L., Law, C., Scher, R., & Pyon, E. (2014). Alogliptin (nesina) for adults with type-2 diabetes. Pharmacy and Therapeutics ,39 (3), 186.
Donate-Correa, J., Luis-Rodríguez, D., Martín-Núñez, E., Tagua, V. G., Hernández-Carballo, C., Ferri, C., Rodríguez-Rodríguez, A. E., Mora-Fernández, C., & Navarro-González, J. F. (2020). Inflammatory targets in diabetic nephropathy. Journal of clinical medicine ,9 (2), 458.
Dong, J., Gong, Y., Liu, J., Chen, X., Wen, X., & Sun, H. (2014). Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin. Bioorganic and Medicinal Chemistry ,22 (4), 1383-1393.
Eizirik, D. L., Pasquali, L., & Cnop, M. (2020). Pancreatic β-cells in type 1 and type 2 diabetes mellitus: different pathways to failure.Nature Reviews Endocrinology , 16 (7), 349-362.
Elkinson, S., & Keating, G. M. (2013). Lixisenatide: first global approval. Drugs , 73 (4), 383-391.
Evans, K. A., Budzik, B. W., Ross, S. A., Wisnoski, D. D., Jin, J., Rivero, R. A., Vimal, M., Szewczyk, G. R., Jayawickreme, C., & Moncol, D. L. (2009). Discovery of 3-aryl-4-isoxazolecarboxamides as TGR5 receptor agonists. Journal of medicinal chemistry , 52 (24), 7962-7965.
Evans, P. M., & Bain, S. C. (2016). Omarigliptin for the treatment of type 2 diabetes mellitus. Expert opinion on pharmacotherapy ,17 (14), 1947-1952.
FARES, M., AL-ANI, I., HAILAT, M., KHALEEL, A., COLLIER, P., AL-ANI, A., & DAYYIH, W. A. (2021). Evaluation the Impact of Grapefruit Juice on Sitagliptin Pharmacokinetics in Healthy Rats. International Journal of Pharmaceutical Research , 13 (2).
Fayyaz, S., Ahmed, D., Khalid, S., Khan, S. N., Shah, M. R., & Choudhary, M. I. (2020). Synthesis of vildagliptin conjugated metal nanoparticles for type II diabetes control: targeting the DPP-IV enzyme.New Journal of Chemistry , 44 (47), 20853-20860.
Feng, J., Zhang, Z., Wallace, M. B., Stafford, J. A., Kaldor, S. W., Kassel, D. B., Navre, M., Shi, L., Skene, R. J., & Asakawa, T. (2007). Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. Journal of medicinal chemistry , 50 (10), 2297-2300.
Foretz, M., Guigas, B., & Viollet, B. (2019). Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.Nature Reviews Endocrinology , 15 (10), 569-589.
Frías, J. P. (2020). Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Review of Endocrinology & Metabolism , 15 (6), 379-394.
[Record #202 is using a reference type undefined in this output style.]
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020). Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens. Diabetes, Obesity and Metabolism , 22 (6), 938-946.
Friedrich, C., Ring, A., Brand, T., Sennewald, R., Graefe-Mody, E., & Woerle, H.-J. (2011). Evaluation of the pharmacokinetic interaction after multiple oral doses of linagliptin and digoxin in healthy volunteers. European journal of drug metabolism and pharmacokinetics , 36 (1), 17-24.
Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K. B., Ostolaza, H., & Martín, C. (2020). Pathophysiology of type 2 diabetes mellitus. International journal of molecular sciences , 21 (17), 6275.
Gao, J., Shi, Z., Zhu, S., Li, G. Q., Yan, R., & Yao, M. (2013). Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches. Journal of ethnopharmacology ,145 (2), 566-572.
Goda, M., & Kadowaki, T. (2013). Teneligliptin for the treatment of type 2 diabetes. Drugs of Today (Barcelona, Spain: 1998) ,49 (10), 615-629.
Graefe-Mody, U., Retlich, S., & Friedrich, C. (2012). Clinical pharmacokinetics and pharmacodynamics of linagliptin. Clinical pharmacokinetics , 51 (7), 411-427.
Granhall, C., Donsmark, M., Blicher, T. M., Golor, G., Søndergaard, F. L., Thomsen, M., & Bækdal, T. A. (2019). Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clinical pharmacokinetics , 58 (6), 781-791.
Granhall, C., Søndergaard, F. L., Thomsen, M., & Anderson, T. W. (2018). Pharmacokinetics, safety and tolerability of oral semaglutide in subjects with renal impairment. Clinical pharmacokinetics ,57 (12), 1571-1580.
Gu, N., Park, S.-I., Chung, H., Jin, X., Lee, S., & Kim, T.-E. (2020). Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. Translational and clinical pharmacology , 28 (1), 17.
Gutch, M., Joshi, A., Kumar, S., Agarwal, A., Pahan, R. K., & Razi, S. M. (2017). Gemigliptin: newer promising gliptin for type 2 diabetes mellitus. Indian journal of endocrinology and metabolism ,21 (6), 898.
Habib, H. A., Heeba, G. H., & Khalifa, M. M. (2021). Comparative effects of incretin-based therapy on early-onset diabetic nephropathy in rats: Role of TNF-α, TGF-β and c-caspase-3. Life Sciences ,278 , 119624.
Halabi, A., Maatouk, H., Siegler, K. E., Faisst, N., Lufft, V., & Klause, N. (2013). Pharmacokinetics of teneligliptin in subjects with renal impairment. Clinical pharmacology in drug development ,2 (3), 246-254.
Hall, S., Isaacs, D., & Clements, J. N. (2018). Pharmacokinetics and clinical implications of semaglutide: a new glucagon-like peptide (GLP)-1 receptor agonist. Clinical pharmacokinetics ,57 (12), 1529-1538.
He, H., Tran, P., Yin, H., Smith, H., Batard, Y., Wang, L., Einolf, H., Gu, H., Mangold, J. B., & Fischer, V. (2009). Absorption, metabolism, and excretion of [14C] vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug metabolism and disposition ,37 (3), 536-544.
He, Y.-L. (2012). Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clinical pharmacokinetics , 51 (3), 147-162.
He, Y.-L., Serra, D., Wang, Y., Campestrini, J., Riviere, G.-J., Deacon, C. F., Holst, J. J., Schwartz, S., Nielsen, J. C., & Ligueros-Saylan, M. (2007). Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. Clinical pharmacokinetics , 46 (7), 577-588.
Hedrington, M. S., & Davis, S. N. (2019). Oral semaglutide for the treatment of type 2 diabetes. Expert opinion on pharmacotherapy ,20 (2), 133-141.
Herman, G. A., Stevens, C., Van Dyck, K., Bergman, A., Yi, B., De Smet, M., Snyder, K., Hilliard, D., Tanen, M., & Tanaka, W. (2005). Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double‐blind, placebo‐controlled studies with single oral doses. Clinical Pharmacology and Therapeutics , 78 (6), 675-688.
Hossain, U., Das, A. K., Ghosh, S., & Sil, P. C. (2020). An overview on the role of bioactive α-glucosidase inhibitors in ameliorating diabetic complications. Food and Chemical Toxicology , 111738.
Hu, P., Yin, Q., Deckert, F., Jiang, J., Liu, D., Kjems, L., Dole, W. P., & He, Y. L. (2009). Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers. The Journal of Clinical Pharmacology , 49 (1), 39-49.
Ishiguro, N., Shimizu, H., Kishimoto, W., Ebner, T., & Schaefer, O. (2013). Evaluation and prediction of potential drug-drug interactions of linagliptin using in vitro cell culture methods. Drug Metabolism and Disposition , 41 (1), 149-158.
Jackson, S. H., Martin, T. S., Jones, J. D., Seal, D., & Emanuel, F. (2010). Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. Pharmacy and Therapeutics ,35 (9), 498.
Jacobsen, L. V., Flint, A., Olsen, A. K., & Ingwersen, S. H. (2016). Liraglutide in type 2 diabetes mellitus: clinical pharmacokinetics and pharmacodynamics. Clinical pharmacokinetics , 55 (6), 657-672.
Jain, L., Chain, A. S., Tatosian, D. A., Hing, J., Passarell, J. A., Kauh, E. A., & Lai, E. (2019). Pharmacokinetic–pharmacodynamic (dipeptidyl peptidase‐4 inhibition) model to support dose rationale in diabetes patients, including those with renal impairment, for once‐weekly administered omarigliptin. British journal of clinical pharmacology , 85 (12), 2759-2771.
Jensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Karsbøl, J. D., & Pedersen, M. L. (2017). Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species. European Journal of Pharmaceutical Sciences , 104 , 31-41.
Jensen, L., Kupcova, V., Arold, G., Pettersson, J., & Hjerpsted, J. B. (2018). Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment. Diabetes, Obesity and Metabolism ,20 (4), 998-1005.
Kadowaki, T., Haneda, M., Ito, H., Sasaki, K., Matsukawa, M., & Yamada, Y. (2020). Long-term, real-world safety and efficacy of teneligliptin: a post-marketing surveillance of more than 10,000 patients with type 2 diabetes in Japan. Advances in therapy , 37 (3), 1065-1086.
Kadowaki, T., Inagaki, N., Kondo, K., Nishimura, K., Kaneko, G., Maruyama, N., Nakanishi, N., Gouda, M., Iijima, H., & Watanabe, Y. (2018). Efficacy and safety of teneligliptin added to canagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: A multicentre, randomized, double‐blind, placebo‐controlled, parallel‐group comparative study. Diabetes, Obesity and Metabolism , 20 (2), 453-457.
Kadowaki, T., Seino, Y., Kaku, K., Okamoto, T., Kameya, M., Sato, A., Hirano, T., Oshima, N., Gantz, I., & O’Neill, E. A. (2021). A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycaemic control. Diabetes, Obesity and Metabolism , 23 (6), 1242-1251.
Kalhotra, P., Chittepu, V. C., Osorio-Revilla, G., & Gallardo-Velázquez, T. (2018). Structure–activity relationship and molecular docking of natural product library reveal chrysin as a novel dipeptidyl peptidase-4 (dpp-4) inhibitor: An integrated in silico and in vitro study. Molecules , 23 (6), 1368.
Kang, W. Y., Lee, H. W., Gwon, M.-R., Cho, S., Shim, W.-S., Lee, K.-T., Yang, D. H., Seong, S. J., & Yoon, Y.-R. (2020). A Pharmacokinetic Drug Interaction Between Fimasartan and Linagliptin in Healthy Volunteers.Drug design, development and therapy , 14 , 2101.
Karim, A., Covington, P., Christopher, R., Davenport, M., Fleck, P., Li, X., Wann, E., & Mekki, Q. (2010). Pharmacokinetics of alogliptin when administered with food, metformin, or cimetidine: a two-phase, crossover study in healthy subjects. International journal of clinical pharmacology and therapeutics , 48 (1), 46-58.
Keating, G. M. (2010). Vildagliptin. Drugs , 70 (16), 2089-2112.
Kim, N., Patrick, L., Mair, S., Stevens, L., Ford, G., Birks, V., & Lee, S.-H. (2014). Absorption, metabolism and excretion of [14C] gemigliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans.Xenobiotica , 44 (6), 522-530.
Kim, S.-H., Lee, S.-H., & Yim, H.-J. (2013). Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry. Archives of pharmacal research , 36 (10), 1185-1188.
Kim, S.-H., Yoo, J.-H., Lee, W. J., & Park, C.-Y. (2016). Gemigliptin: an update of its clinical use in the management of type 2 diabetes mellitus. Diabetes & metabolism journal , 40 (5), 339-353.
Kinoshita, S., & Kondo, K. (2015). Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers. Expert Opinion on Drug Metabolism and Toxicology , 11 (1), 7-14.
Kolterman, O. G., Kim, D. D., Shen, L., Ruggles, J. A., Nielsen, L. L., Fineman, M. S., & Baron, A. D. (2005). Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. American Journal of Health-System Pharmacy ,62 (2), 173-181.
Krishna, R., Addy, C., Tatosian, D., Glasgow, X. S., Gendrano III, I. N., Robberechts, M., Haazen, W., de Hoon, J., Depré, M., & Martucci, A. (2016). Pharmacokinetics and pharmacodynamics of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor, after single and multiple doses in healthy subjects. The Journal of Clinical Pharmacology , 56 (12), 1528-1537.
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., & Steensgaard, D. B. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of medicinal chemistry ,58 (18), 7370-7380.
Lee, B., Shi, L., Kassel, D. B., Asakawa, T., Takeuchi, K., & Christopher, R. J. (2008). Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys. European journal of pharmacology , 589 (1-3), 306-314.
Lee, Y.-h., Kim, J. H., Kim, S. R., Jin, H. Y., Rhee, E.-J., Cho, Y. M., & Lee, B.-W. (2017). Lobeglitazone, a novel thiazolidinedione, improves non-alcoholic fatty liver disease in type 2 diabetes: its efficacy and predictive factors related to responsiveness. Journal of Korean medical science , 32 (1), 60-69.
Leiter, L. A., Gómez-Huelgas, R., Ambos, A., Arteaga, J. M., Marchesini, G., Nikonova, E., Shestakova, M., Stager, W., Tambascia, M., & Hanefeld, M. (2014). Lixisenatide is effective and well tolerated in patients with type 2 diabetes mellitus and renal impairment.Canadian Journal of Diabetes , 38 (5), S10-S11.
Li, Q., Deng, X., Jiang, N., Meng, L., Xing, J., Jiang, W., & Xu, Y. (2021). Identification and structure–activity relationship exploration of uracil-based benzoic acid and ester derivatives as novel dipeptidyl Peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus.European Journal of Medicinal Chemistry , 225 , 113765.
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020). An evaluation of liraglutide including its efficacy and safety for the treatment of obesity. Expert opinion on pharmacotherapy , 21 (3), 275-285.
Linnebjerg, H., Kothare, P. A., Park, S., Mace, K., Reddy, S., Mitchell, M., & Lins, R. (2007). Effect of renal impairment on the pharmacokinetics of exenatide. British journal of clinical pharmacology , 64 (3), 317-327.
Ludvik, B., Giorgino, F., Jódar, E., Frias, J. P., Landó, L. F., Brown, K., Bray, R., & Rodríguez, Á. (2021). Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. The Lancet ,398 (10300), 583-598.
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010). Metabolism and excretion of the once-daily human glucagon-like peptide-1 analog liraglutide in healthy male subjects and its in vitro degradation by dipeptidyl peptidase IV and neutral endopeptidase. Drug Metabolism and Disposition , 38 (11), 1944-1953.
Mann, J. L., Maikawa, C. L., Smith, A. A., Grosskopf, A. K., Baker, S. W., Roth, G. A., Meis, C. M., Gale, E. C., Liong, C. S., & Correa, S. (2020). An ultrafast insulin formulation enabled by high-throughput screening of engineered polymeric excipients. Science translational medicine , 12 (550).
[Record #197 is using a reference type undefined in this output style.]
Mcfarlane, M., Liu, B., & Nwokolo, C. (2018). Domperidone prolongs oral to duodenal transit time in video capsule endoscopy. European Journal of Clinical Pharmacology , 74 (4), 521-524.
Migoya, E. M., Stevens, C. H., Bergman, A. J., Luo, W.-l., Lasseter, K. C., Dilzer, S. C., Davies, M. J., Wagner, J. A., & Herman, G. A. (2009). Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin. Journal of Population Therapeutics and Clinical Pharmacology , 16 (1).
Moon, S. J., Yu, K.-S., & Kim, M.-G. (2020). An assessment of pharmacokinetic interaction between lobeglitazone and sitagliptin after multiple oral administrations in healthy men. Clinical therapeutics , 42 (6), 1047-1057.
Morimoto, K., Sasaki, M., Oikawa, E., Abe, M., Kikuchi, T., Ishii, M., Ogihara, T., & Tomita, M. (2021). Intestinal Absorption of Alogliptin Is Mediated by a Fruit-Juice-Sensitive Transporter. Biological and Pharmaceutical Bulletin , 44 (5), 653-658.
Morrow, L., Hompesch, M., Guthrie, H., Chang, D., & Chatterjee, D. (2011). Co‐administration of liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no pharmacokinetic interaction. Diabetes, Obesity and Metabolism , 13 (1), 75-80.
Nakamaru, Y., Hayashi, Y., Ikegawa, R., Kinoshita, S., Madera, B. P., Gunput, D., Kawaguchi, A., Davies, M., Mair, S., & Yamazaki, H. (2014). Metabolism and disposition of the dipeptidyl peptidase IV inhibitor teneligliptin in humans. Xenobiotica , 44 (3), 242-253.
Nangaku, M., & Wanner, C. (2021). Not only incretins for diabetic kidney disease—beneficial effects by DPP-4 inhibitors. Kidney International , 99 (2), 318-322.
Nauck, M. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes, Obesity and Metabolism , 18 (3), 203-216.
Nauck, M. A., & Meier, J. J. (2018). Incretin hormones: their role in health and disease. Diabetes, Obesity and Metabolism , 20 , 5-21.
Nielsen, L. L., Young, A. A., & Parkes, D. G. (2004). Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regulatory peptides ,117 (2), 77-88.
Noh, Y.-H., Lim, H.-S., Jin, S.-J., Kim, M. J., Kim, Y. H., Sung, H. R., Choi, H. Y., & Bae, K.-S. (2012). Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug–drug interaction study in healthy male Korean volunteers. Clinical therapeutics ,34 (5), 1182-1194.
Norris, J. M., Johnson, R. K., & Stene, L. C. (2020). Type 1 diabetes—early life origins and changing epidemiology. The Lancet Diabetes & Endocrinology , 8 (3), 226-238.
Packer, M. (2021). Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes.JACC: Heart Failure , 9 (8), 535-549.
Parsa, K. V., & Pal, M. (2011). Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview. Expert opinion on drug discovery , 6 (8), 855-869.
Peng, W., Rao, D., Zhang, M., Shi, Y., Wu, J., Nie, G., & Xia, Q. (2020). Teneligliptin prevents doxorubicin-induced inflammation and apoptosis in H9c2 cells. Archives of biochemistry and biophysics ,683 , 108238.
Quast, D. R., Schenker, N., Menge, B. A., Nauck, M. A., Kapitza, C., & Meier, J. J. (2020). Effects of lixisenatide versus liraglutide (short-and long-acting GLP-1 receptor agonists) on esophageal and gastric function in patients with type 2 diabetes. Diabetes Care ,43 (9), 2137-2145.
Rendell, M. S. (2016). Albiglutide: a unique GLP-1 receptor agonist.Expert opinion on biological therapy , 16 (12), 1557-1569.
Rendell, M. S. (2018). Albiglutide for the management of type 2 diabetes. Expert review of endocrinology & metabolism ,13 (1), 1-8.
Röhrborn, D., Wronkowitz, N., & Eckel, J. (2015). DPP4 in diabetes.Frontiers in immunology , 6 , 386.
Saltiel, A. R., & Olefsky, J. M. (1996). Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes ,45 (12), 1661-1669.
Sanford, M. (2014). Dulaglutide: first global approval. Drugs ,74 (17), 2097-2103.
Scheen, A. J. (2017). Dulaglutide for the treatment of type 2 diabetes.Expert opinion on biological therapy , 17 (4), 485-496.
Scott, L. J. (2010). Alogliptin. Drugs , 70 (15), 2051-2072.
Shon, J., Kim, N., Park, S., Oh, M., Kim, E., Lee, S., Kim, Y., & Shin, J. (2014). Effect of renal impairment and haemodialysis on the pharmacokinetics of gemigliptin (LC15‐0444). Diabetes, Obesity and Metabolism , 16 (10), 1028-1031.
Stofella, N. C., Veiga, A., Oliveira, L. J., Montin, E. F., Andreazza, I. F., Carvalho Filho, M. A., Bernardi, L. S., Oliveira, P. R., & Murakami, F. S. (2019). Solid-state characterization of different crystalline forms of sitagliptin. Materials , 12 (15), 2351.
Su, H., Boulton, D. W., Barros, A., Wang, L., Cao, K., Bonacorsi, S. J., Iyer, R. A., Humphreys, W. G., & Christopher, L. J. (2012). Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metabolism and Disposition , 40 (7), 1345-1356.
Thomas, M. K., Nikooienejad, A., Bray, R., Cui, X., Wilson, J., Duffin, K., Milicevic, Z., Haupt, A., & Robins, D. A. (2021). Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in Type 2 diabetes. The Journal of Clinical Endocrinology & Metabolism , 106 (2), 388-396.
Trujillo, J. M., & Nuffer, W. (2014). Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Annals of Pharmacotherapy , 48 (11), 1494-1501.
Upreti, V. V., Boulton, D. W., Li, L., Ching, A., Su, H., LaCreta, F. P., & Patel, C. G. (2011). Effect of rifampicin on the pharmacokinetics and pharmacodynamics of saxagliptin, a dipeptidyl peptidase‐4 inhibitor, in healthy subjects. British journal of clinical pharmacology ,72 (1), 92-102.
Urva, S., Coskun, T., Loghin, C., Cui, X., Beebe, E., O’Farrell, L., Briere, D. A., Benson, C., Nauck, M. A., & Haupt, A. (2020). The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists. Diabetes, Obesity and Metabolism , 22 (10), 1886-1891.
Urva, S., Quinlan, T., Landry, J., Martin, J., Loghin, C., & Goergens, S. (2021). Renal impairment has no impact on the clinical pharmacokinetics of tirzepatide. Diabetologie und Stoffwechsel ,16 (S 01).
Use, C. f. M. P. f. H. (2013). European Medicines Agency. European Public Assessment Report: procedure no .
van Netten, J. J., Bus, S. A., Apelqvist, J., Lipsky, B. A., Hinchliffe, R. J., Game, F., Rayman, G., Lazzarini, P. A., Forsythe, R. O., & Peters, E. J. (2020). Definitions and criteria for diabetic foot disease. Diabetes/metabolism research and reviews , 36 , e3268.
Vincent, S. H., Reed, J. R., Bergman, A. J., Elmore, C. S., Zhu, B., Xu, S., Ebel, D., Larson, P., Zeng, W., & Chen, L. (2007). Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans. Drug metabolism and disposition , 35 (4), 533-538.
Vora, A., Varghese, A., Kachwala, Y., Laddha, A. P., Bhaskar, M., Akhtar, J., & Yadav, P. (2020). Pharmacokinetic and pharmacodynamic interactions of Tinospora cordifolia aqueous extract and hypoglycemic drugs in streptozotocin-induced diabetes in rats. Pharmacognosy Magazine , 16 (68), 47.
Weber, A. E., & Thornberry, N. (2007). Case History: JANUVIA™(Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. Annual Reports in Medicinal Chemistry , 42 , 95-109.
Werner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010). Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regulatory peptides ,164 (2-3), 58-64.
Willard, F. S., Douros, J. D., Gabe, M. B., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J., Stutsman, C., & Cardona, G. R. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI insight , 5 (17).
Xie, C., Huang, W., Watson, L. E., Soenen, S., Young, R. L., Jones, K. L., Horowitz, M., Rayner, C. K., & Wu, T. (2021). Plasma GLP-1 response to oral and intraduodenal nutrients in health and type 2 diabetes–impact on gastric emptying. The Journal of Clinical Endocrinology & Metabolism .
Xu, G., Liu, B., Sun, Y., Du, Y., Snetselaar, L. G., Hu, F. B., & Bao, W. (2018). Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. Bmj , 362 .
Xu, S., Tatosian, D., Mcintosh, I., Caceres, M., Matthews, C., Samuel, K., Selverian, D., Kumar, S., & Kauh, E. (2018). Absorption, metabolism and excretion of [14C] omarigliptin, a once-weekly DPP-4 inhibitor, in humans. Xenobiotica , 48 (6), 584-591.
Yang, L. P. (2012). Saxagliptin. Drugs , 72 (2), 229-248.
Yaribeygi, H., Rashidy-Pour, A., Atkin, S. L., Jamialahmadi, T., & Sahebkar, A. (2020). GLP-1 mimetics and cognition. Life Sciences , 118645.
Yoon, S. A., Han, B. G., Kim, S. G., Han, S. Y., Jo, Y. I., Jeong, K. H., Oh, K. H., Park, H. C., Park, S. H., & Kang, S. W. (2017). Efficacy, safety and albuminuria‐reducing effect of gemigliptin in K orean type 2 diabetes patients with moderate to severe renal impairment: A 12‐week, double‐blind randomized study (the GUARD S tudy).Diabetes, Obesity and Metabolism , 19 (4), 590-598.
Yoshikawa, K., Tsuchiya, A., Kido, T., Ota, T., Ikeda, K., Iwakura, M., Maeda, Y., & Maekawa, S. (2020). Long-Term Safety and Efficacy of Sitagliptin for Type 2 Diabetes Mellitus in Japan: Results of a Multicentre, Open-Label, Observational Post-Marketing Surveillance Study. Advances in therapy , 37 (5), 2442-2459.
Young, M. A., Wald, J. A., Matthews, J. E., Scott, R., Hodge, R. J., Zhi, H., & Reinhardt, R. R. (2014). Clinical pharmacology of albiglutide, a GLP-1 receptor agonist. Postgraduate medicine ,126 (7), 84-97.